65岁及以上患者外科与经导管主动脉瓣置换对比
基于美国Medicare数据库2018-2022年数据,评估65-85岁首次单纯行SAVR(n=34,215)或TAVR(n=124,897)的患者。按预测风险分层后,SAVR在各风险层院内死亡率、急性肾损伤和出血更高但起搏器率更低;低中风险患者SAVR的5年复合终点(死亡、卒中或瓣膜再干预)更优。
要点
- 低中危患者SAVR的5年无死亡、卒中或再干预生存优于TAVR。
- 各风险层SAVR院内死亡率、急性肾损伤和出血高于TAVR。
- SAVR起搏器植入率低于TAVR。
核心结论
- 在低危和中危Medicare受益者中,SAVR与较高的院内死亡率相关,但5年无死亡、卒中或瓣膜再干预生存优于TAVR。
研究设计与样本
- 基于美国Centers for Medicare Services数据库的回顾性队列研究,纳入2018-2022年65-85岁首次单纯SAVR(n=34,215)或TAVR(n=124,897)患者。
- 采用逆概率加权和多层回归竞争风险时间-事件分析进行双重稳健风险调整。
- 按模拟STS预测手术死亡率并纳入衰弱的预测风险分为低危(<4%)、中危(4%-8%)和高危(>8%)三层。
主要发现
- 各风险层SAVR的院内死亡率、急性肾损伤和出血均高于TAVR(均P < .05)。
- 各风险层SAVR起搏器植入率低于TAVR(P < .05)。
- 低危患者SAVR的5年复合终点(死亡、卒中或瓣膜再干预)HR 0.85(P = .044)。
- 中危患者SAVR的5年复合终点HR 0.86(P = .039)。
- 低危患者卒中再入院HR 0.72(P = .038),中危患者HR 0.78(P = .042)。
临床怎么用
- 心脏团队决策时应综合考虑:低中危患者SAVR虽院内结局较差但5年复合终点更优,需结合患者偏好与风险评估个体化选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approval of transcatheter aortic valve replacement (TAVR) for all risk profiles has extended TAVR use in patients not otherwise examined in clinical trials. We sought to evaluate contemporary real-world outcomes of surgical aortic valve replacement (SAVR) vs TAVR in Medicare beneficiaries by risk strata. METHODS: Using the US Centers for Medicare Services database, all patients aged 65-85 years undergoing isolated first-time SAVR (n = 34,215) or TAVR (n = 124,897) were evaluated (2018-2022). Predicted patient risk accounting for comorbidities simulating The Society of Thoracic Surgeons predicted risk of surgical mortality, but including frailty, were stratified by low (<4%, n = 36,297 TAVR; n = 14,693 SAVR), intermediate (4%-8%, n = 44,026 TAVR; n = 9693 SAVR), or high (>8%, n = 44,574 TAVR; n = 9841 SAVR) risk. Doubly robust risk adjustment with inverse probability weighting and multilevel regression with competing-risk time-to-event analyses compared outcomes. RESULTS: SAVR was associated with higher risk-adjusted in-hospital mortality, acute kidney injury, and bleeding but lower pacemaker rate compared with TAVR across all risk strata (all P < .05). Longitudinal 5-year analysis highlighted that, compared with TAVR, SAVR was associated with superior freedom from composite death, stroke, or valve reintervention in low- and intermediate-risk patients (hazard ratio [HR] 0.85, P = .044, and HR 0.86, P = .039, respectively) as well as lower overall readmission for stroke in low- (HR 0.72, P = .038) and intermediate- (HR 0.78, P = .042) risk patients. CONCLUSIONS: In low- and intermediate-risk Medicare beneficiaries, SAVR was associated with higher in-hospital mortality but superior 5-year longitudinal freedom from death, stroke, or valve reintervention compared to TAVR. These data may further enhance heart team decision-making and patient counseling.
引用
- Wolfe S, Jagadeesan V, Wei L, et al. Surgical vs Transcatheter Aortic Valve Replacement in Patients 65 Years of Age and Older. Ann Thorac Surg. 2025. PMID: 40015547. doi:10.1016/j.athoracsur.2025.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。